Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction - PubMed
4 hours ago
- #Child-Pugh Score
- #Immunotherapy
- #Hepatocellular Carcinoma
- Phase II trial assessed nivolumab and sorafenib in advanced HCC patients with varying liver function.
- Safety and efficacy were evaluated, with Dose Level -1 identified as the maximum-tolerated dose (MTD).
- 69% of patients experienced Grade ≥3 treatment-related adverse events (TRAEs), with similar rates in Child-Pugh A and B subgroups.
- Objective response rate was low (6%), with median overall survival of 12.99 months (15.26 for Child-Pugh A, 10.41 for Child-Pugh B).
- Child-Pugh B patients had higher levels of immunosuppressive CD14+ monocytes at baseline, suggesting a distinct immune profile.
- The study highlights the need for better therapies in HCC patients with impaired liver function and provides insights into resistance mechanisms.